Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06296056
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-06
First Post:
2024-02-20
Brief Title:
Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care
Sponsor:
Nyamdavaa Tuul
Organization:
Seoul Hospital
Study Overview
Official Title:
A Phase І Single Center Clinical Trial to Evaluate the Safety Immune Response and Efficacy of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Have Failed Prior Standard of Care
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety immune response and potential efficacy of combined immune cell therapy in patients with stage 4 colorectal cancer who have failed standard treatment and have unresectable lesions or metastatic lesions
Detailed Description:
The combined immune cell therapy has a strong potential to improve treatment outcomes in several cancers but problems related to manufacturing complexity immunocompatibility and poteintial toxicity may also arise This clinical study was designed to address these challenges and to establish the safety and potential efficacy of combined immune cell therapy for unresectable colorectal cancer This is a phase I study to evaluate the safety and potential efficacy of combined immune cell theapy and obtain the recommended dose and infusion plan
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None